We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Panel Recommends Rejection of AstraZeneca Cancer Drug
FDA Panel Recommends Rejection of AstraZeneca Cancer Drug
FDA advisors want more clinical data before recommending a green light for AstraZeneca’s latest ovarian cancer treatment, dealing a blow to the British drugmaker’s promising oncology pipeline.